FAQ

anti-CD137 monoclonal antibody

Known as: Anti-4-1BB Monoclonal Antibody, Immunoglobulin G4, Anti-(Human Receptor 4-1BB) (Human Gamma-Chain), Disulfide with Human Kappa-Chain, Dimer, Urelumab 
A fully human agonistic monoclonal antibody targeting the CD137 receptor with potential immunostimulatory and antineoplastic activities. Anti-CD137… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1999-2017
012319992017

Related topics

Related topics

5 relations
Antibody-Dependent Cellular CytotoxicityB-LymphocytesCytotoxic T-Lymphocytesantigen binding

Narrower (1)

BMS-663513

Related mentions per year

Related mentions per year

1948-2018
19401960198020002020
anti-CD137 monoclonal antibody
B-Lymphocytes
Cytotoxic T-Lymphocytes
Antibody-Dependent Cellular Cytotoxicity
antigen binding
BMS-663513

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.
Purpose: Urelumab is an agonist antibody to CD137 with potential application as an immuno-oncology therapeutic. Data were… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2017
2017
CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
PURPOSE Cetuximab, an EGFR-specific antibody (mAb), modestly improves clinical outcome in patients with head and neck cancer (HNC… (More)
Is this relevant?
2017
2017
4-1BB-Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells.
Triple-negative breast cancer (TNBC) highly infiltrated with CD8+ tumor-infiltrating lymphocytes (TIL) has been associated with… (More)
Is this relevant?
2015
2015
Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice.
A current pressing need in cancer immunology is the development of preclinical model systems that are immunocompetent for the… (More)
Is this relevant?
2015
2015
Functional expression of CD137 (4-1BB) on T helper follicular cells.
CD137 (4-1BB) is a surface protein initially discovered to mark activated T lymphocytes. However, its broader expression pattern… (More)
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types.
Modulation of the immune system by targeting coinhibitory and costimulatory receptors has become a promising new approach of… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2013
2013
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
Recent investigations of the tumor microenvironment have shown that many tumors are infiltrated by inflammatory and lymphocytic… (More)
  • table 1
Is this relevant?
2009
2009
Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy.
Chemotherapy can precondition for immunotherapy by creating an environment for homeostatic lymphoproliferation and eliminating… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2004
2004
Infection-induced up-regulation of the costimulatory molecule 4-1BB in osteoblastic cells and its inhibitory effect on M-CSF/RANKL-induced in vitro osteoclastogenesis.
Bacterial infection sometimes impairs bone metabolism. In this study, we infected the osteoblastic cell line MC3T3-E1 with… (More)
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Anti–4-1bb Monoclonal Antibodies Abrogate T Cell–Dependent Humoral Immune Responses in Vivo through the Induction of Helper T Cell Anergy
The 4-1BB receptor (CDw137), a member of the tumor necrosis factor receptor superfamily, has been shown to costimulate the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 5
Is this relevant?